A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

October 11, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Breast Cancer

Interventions

DRUG

HB1801

HB1801 \[administered according to the clinical trial protocol\]

DRUG

Taxotere®

Taxotere® 75 mg/ m\^2 \[administered according to the clinical trial protocol\]\]

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY